Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...